
-
Amneal Pharmaceuticals Inc. NEW YORK STOCK EXCHANGE INC.:AMRX Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.
Location: 400 Crossing Blvd Fl 3, New Jersey, 08807-2863, US | Website: www.amneal.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
5.078B
Cash
112.4M
Avg Qtr Burn
N/A
Short % of Float
2.03%
Insider Ownership
48.68%
Institutional Own.
41.28%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PEMRYDI RTU® Details Small cell lung cancer, Malignant pleural/peritoneal mesothelioma | Approved Update | |
OTC NARCAN® HCI Nasal Spray Details Opioid overdose | Approved Quarterly sales | |
Xyrem® (sodium oxybate) Generic Details Narcolepsy | Approved Quarterly sales | |
CREXONT® (Carbidopa & Levodopa) (IPX203) Details Parkinson's disease | Approved Quarterly sales | |
RELEUKO® (filgrastim-ayow) Details Chemotherapy-induced neutropenia | Approved Quarterly sales | |
BORUZU (Bortezomib) Details Multiple myeloma, Mantle cell lymphoma | Approved Quarterly sales | |
Potassium Phosphates Injection IV Bags Details Hypophosphatemia | Approved Quarterly sales | |
Lisdexamfetamine Dimesylate Details Attention deficit hyperactivity disorder | Approved Quarterly sales | |
Denosumab Biosimilars Details Osteoporosis | PDUFA Approval decision | |
NDA Acceptance for review |